XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Additions and Returns of Product Rights - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended 24 Months Ended
Nov. 30, 2018
Nov. 30, 2016
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2021
Jul. 31, 2020
Business Acquisition [Line Items]            
Financial consideration received in exchange for product license rights, installment payments     $ 500,000 $ 3,000,000.0    
Clinigen | Scenario, Forecast            
Business Acquisition [Line Items]            
Financial consideration received in exchange for product license rights         $ 5,000,000  
Vaprisol            
Business Acquisition [Line Items]            
Payment to acquire business upon closing $ 20,000,000.0          
Other Payments to Acquire Businesses $ 5,000,000.0          
Percentage of tiered royalty payments (up to) 20.00%          
Additional liability     7,336,045 8,200,552    
Vaprisol | Other current liabilities            
Business Acquisition [Line Items]            
Additional liability     2,700,000      
Vaprisol | Other long-term liabilities            
Business Acquisition [Line Items]            
Additional liability     4,600,000      
Methotrexate            
Business Acquisition [Line Items]            
Payment to acquire business upon closing   $ 100,000        
Additional liability       $ 1,000,000.0   $ 1,000,000.0
Liability recorded   $ 900,000        
Vested common stock, value     900,000      
Net intangible assets     $ 2,800,000      
Methotrexate | Restricted Stock            
Business Acquisition [Line Items]            
Unvested restricted shares (in shares)   180,000